Marshall Wace North America’s Heron Therapeutics HRTX Stock Holding History

Marshall Wace North America’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$282K	Buy	+26,362	New	+$321K	﹤0.01%	1263
2019 Q2	–	Sell	-4,522	Closed	-$111K	–	1338
2019 Q1	$111K	Sell	4,522 -6,815	-60%	-$178K	﹤0.01%	1097
2018 Q4	$294K	Buy	+11,337	New	+$312K	﹤0.01%	892
2018 Q3	–	Sell	-156,298	Closed	-$6.07M	–	1109
2018 Q2	$6.07M	Buy	+156,298	New	+$4.98M	0.03%	468

Other funds holding HRTX

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Marshall Wace North America's HRTX Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Heron Therapeutics (HRTX) in Q3 2021: 26,362 shares worth $282K. The stake represents ﹤0.01% of the portfolio and ranks #1263 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in HRTX as recently as Q1 2019.

Marshall Wace North America first reported a position in HRTX in Q2 2018 and has held it in 4 quarters since. The position peaked at $6.07M in Q2 2018. 197 funds tracked by Wall St. Rank hold HRTX as of Q3 2021.

Marshall Wace North America held 26,362 shares of Heron Therapeutics worth $282K as of Q3 2021.
Heron Therapeutics was a new Marshall Wace North America position in Q3 2021.
Heron Therapeutics made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1263 holding.
Marshall Wace North America first reported a position in Heron Therapeutics in Q2 2018 and has held it in 4 quarters since.
Marshall Wace North America's Heron Therapeutics position peaked at $6.07M in Q2 2018.
197 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.